|
|
Themen-Optionen | Ansicht |
#10
|
||||
|
||||
AW: Wer hat Erfahrung mit Rituximab Monotherapie als Primärtherapie?
Zitat:
Zitat:
2014, Maurer et al.: "Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy" Quelle: http://ascopubs.org/doi/full/10.1200/jco.2013.51.5866 Welche Studie meinst du? Hast du evtl. einen Link? Zitat:
Zitat:
So.. und nun noch meine Recherche-Ergebnisse zu der Lebenserwartung. Man beachte die Jahreszahlen: 2012: Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation "Median survival rates have historically reported to be in the range of 8 to 10 years" Quelle: http://www.sciencedirect.com/science...83879111004824 2017, Bruce D. Cheson, U.S. Management of First Relapse Follicular Lymphoma: "Progression of disease within 24 months (POD24) is an accurate predictor of poor overall survival (OS)." Quelle: http://ercongressi.it/Slides_Indolen....%20Cheson.pdf Und nun das beste :-) 2017, Provencio et al., Prognostic Value of Event-Free Survival at 12 and 24 Months and Long-Term Mortality for fNHL Patients "The long-term Standardized mortality ratios, over the course of 10 years of follow-up, shows that patients with FL have a risk of dying similar to that of a sex- and age-matched general population." Quelle: https://www.ncbi.nlm.nih.gov/labs/articles/28608996/
__________________
10-2010 Zufallsdiagnose Lymphom 11-2010 – 04-2011 Staging, Diagnose: FL (Gr I, Stadium 3A), Abdomen u. Hals 05-2011 – 08-2011 W&W 09-2011 – 11-2011 Rituximab mono 4x 12-2011 CR :-) 06-2017 Rezidiv. LK 2cm. W&W. 07-2017 Empfehlung bei Behandlungsindikation: Rituximab mono 4x + ggf. Rituximab-Erhaltung (4x alle 2 Monate, SAKK-Schema) 11-2017 LK 3cm 12-2017 absofort vegan 2018 LK 45mm 2019 absofort ketogen 2019 LK 25mm 02-2020 zusätzlicher Hals-LK 25mm 06-2020 LK 25mm |
Lesezeichen |
Aktive Benutzer in diesem Thema: 1 (Registrierte Benutzer: 0, Gäste: 1) | |
|
|